Compare · IMDX vs LMDX
IMDX vs LMDX
Side-by-side comparison of Insight Molecular Diagnostics Inc. (IMDX) and LumiraDx Limited (LMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMDX and LMDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LMDX is the larger of the two at $2.23B, about 14.6x IMDX ($153.1M).
- IMDX has hit the wire 6 times in the past 4 weeks while LMDX has been quiet.
- LMDX has more recent analyst coverage (4 ratings vs 0 for IMDX).
- Company
- Insight Molecular Diagnostics Inc.
- LumiraDx Limited
- Price
- -
- -
- Market cap
- $153.1M
- $2.23B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 6
- 0
- Recent ratings
- 0
- 4
Latest IMDX
- Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
- Director Silverman Lou covered exercise/tax liability with 7,700 shares, decreasing direct ownership by 12% to 55,807 units (SEC Form 4) (withholding tax)
- Director Last Andrew J. covered exercise/tax liability with 7,700 shares, decreasing direct ownership by 12% to 58,752 units (SEC Form 4) to satisfy withholding obligation
- Director Arno Andrew covered exercise/tax liability with 12,100 shares, decreasing direct ownership by 7% to 156,785 units (SEC Form 4) to cover withholding tax
- IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
- iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry
- Director Silverman Lou was granted 26,943 shares, increasing direct ownership by 74% to 63,507 units (SEC Form 4)
- Director Last Andrew J. was granted 26,943 shares, increasing direct ownership by 68% to 66,452 units (SEC Form 4)
Latest LMDX
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form 6-K filed by LumiraDx Limited
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- LumiraDx shares are trading lower after the company announced its securities will be suspended from trading on Nasdaq at the open of business tomorrow.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
- US Stocks Mixed; Nasdaq Jumps Over 100 Points